TGF-β RI Kinase Inhibitor VI, SB431542-CAS 301836-41-9-Calbiochem

NA.77

A cell-permeable triarylimidazole compound that is shown to effectively inhibit cellular Smad2 phosphorylation (>90% inhibition by 10 µM inhibitor) upon vector-mediated expression of constitutively active ALK4, ALK5, or ALK7 in NIH 3T3 cells, while exhibiting little effect against Smad1 phosphorylation by other members of type I receptors for TGF-β in NIH 3T3 cultures expressing active ALK1, 2, 3, or 6. When tested directly in cell-free kinase assays, SB431542 is demonstrated to potently inhibit the activity of ALK4 and ALK5 (IC₅₀ = 140 nM and 94 nM, respectively) with no or much reduced potency toward a panel of 24 other kinases (IC₅₀ ≥10 µM in the presence of 10 µM ATP), including ALK2 and ALK6. Reported to improve the efficiency of 4-TF-induced human iPSCs generation from fibroblast cultures by >200-fold when used together with PD0325901 (Cat. No. 444966) and Thiazovivin (Cat. No. 420220).

Toxicity: Standard Handling (A)

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

200

≥97% (HPLC)

solid

Calbiochem^®

OK to freeze
protect from light

off-white

ethanol: 10 mg/mL
DMSO: 100 mg/mL

ambient

2-8℃

Packaged under inert gas

11 - Combustible Solids

WGK 3